Melanie Lindsey, MD
Family Medicine · Hattiesburg, MSNPI 1598736605
Payments from drug & device makers
Across 230 payments — averaging $14.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$545
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$440
- AstraZeneca$368
- Amgen$313
- Novo Nordisk$184
- Pfizer$174
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,383100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 54 | $545 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $440 |
| AstraZeneca | 21 | $368 |
| Amgen | 23 | $313 |
| Novo Nordisk | 12 | $184 |
| Pfizer | 11 | $174 |
| Lilly USA, LLC | 10 | $159 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $153 |
| GSK | 10 | $146 |
| Merck | 8 | $118 |
| Teva Pharmaceuticals USA, Inc. | 7 | $108 |
| Genentech USA, Inc. | 5 | $80 |
| Biohaven Pharmaceuticals, Inc. | 4 | $71 |
| Boehringer Ingelheim | 4 | $65 |
| Johnson & Johnson | 4 | $51 |
| Amarin Pharma, Inc. | 3 | $48 |
| Sunovion Pharmaceuticals Inc. | 2 | $47 |
| Abbott | 2 | $46 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Medtronic | 2 | $34 |
| Shield Therapeutics Inc | 2 | $34 |
| Astellas Pharma US Inc | 2 | $26 |
| Mylan Specialty L.p. | 1 | $24 |
| Bayer | 1 | $18 |
| Axonics, Inc. | 1 | $17 |
| Boston Scientific | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
| Novartis | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$3,383 in reported general payments places this provider in the 80th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 63 | $75,471 |
| OzempicSemaglutide | 51 | $61,868 |
| JanuviaSitagliptin Phosphate | 52 | $59,443 |
| MounjaroTirzepatide | 41 | $56,956 |
| EliquisApixaban | 29 | $28,396 |
| TrulicityDulaglutide | 15 | $25,708 |
| FarxigaDapagliflozin Propanediol | 19 | $13,915 |
| XareltoRivaroxaban | 11 | $12,743 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $11,443 |
| MyrbetriqMirabegron | 13 | $7,952 |
| LinzessLinaclotide | 13 | $7,871 |
| BelsomraSuvorexant | 12 | $7,723 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $6,450 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,697 |
| SynthroidLevothyroxine Sodium | 33 | $3,802 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $159 | $82,66556 claims |
| Boehringer IngelheimJardiance | $65 | $75,47163 claims |
| MerckJanuvia, Belsomra | $118 | $67,16764 claims |
| Novo NordiskOzempic | $184 | $61,86851 claims |
| PfizerEliquis | $174 | $28,39629 claims |
| AstraZenecaFarxiga | $368 | $13,91519 claims |
| Johnson & JohnsonXarelto | $51 | $12,74311 claims |
| AbbVieLinzess, Synthroid, Armour Thyroid | $545 | $12,57758 claims |
| Astellas Pharma US IncMyrbetriq | $26 | $7,95213 claims |
| GSKBreo Ellipta | $146 | $4,69712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Hattiesburg
- Rambod RouhbakhshHattiesburg$6M
- Omolara OtaigbeHattiesburg$17K
- Deborah CopelandHattiesburg$13K
- J DumasHattiesburg$12K
- Anny EvansHattiesburg$10K
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.